Mulay James's Form 4 filing
CG Oncology, Inc. (CGON) · filed Oct 10, 2025
- Accession no.
- 0001193125-25-237104
- Filed
- Oct 10, 2025
- Trade date
- Oct 9, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $259.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mulay JamesCIK 0001684531 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 | Common Stock | MOption exerciseAcquired | +5,903 | $3.72 | +$21,959.16 | 5,903 | Direct | |
| Oct 9, 2025 | Common Stock | SSaleDisposed | −5,903 | $43.99 | −$259,672.97 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 | Common Stock | MOption exerciseDisposed | −5,903 | $0.00 | $0 | 1,962 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.